华法林与炔诺酮潜在药物相互作用:青少年女性病例系列
该病例系列报告3例机械二尖瓣置换术后青少年女性,因月经过多启用炔诺酮后国际标准化比值(INR)升高,需在5至12周内将华法林周剂量最多下调50%。提示炔诺酮可能增强华法林抗凝作用,建议合用及停用时密切监测INR并积极调整剂量。
要点
- 炔诺酮可能增强华法林抗凝效应,导致INR升高。
- 启用炔诺酮后5至12周内华法林周剂量最多需减少50%。
- 合用或停用炔诺酮期间应密切监测INR并调整华法林剂量。
核心结论
- 炔诺酮用于管理月经过多可能显著增强华法林的抗凝作用。
研究设计与样本
- 病例系列,纳入3例有机械二尖瓣置换史并发生月经过多的青少年女性。
主要发现
- 3例患者在启用炔诺酮前华法林方案稳定,启用后INR升高。
- 为应对INR升高,患者在5至12周内需将华法林周剂量最多减少50%。
关键数值与推荐
- 华法林周剂量最多减少50%,调整时间为5至12周。
临床怎么用
- 对使用华法林的患者,在启用或停用炔诺酮时应密切监测INR并积极调整华法林剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In the pediatric population, warfarin remains the recommended oral anticoagulant for valvular heart disease. Warfarin carries a risk of bleeding complications that can manifest as heavy menstrual bleeding (HMB) in postmenarchal adolescent females. As a result, these patients may be started on hormonal therapies, such as norethindrone, to suppress menstruation. SUMMARY: This case series describes a potential drug interaction between warfarin and norethindrone in 3 adolescent females with a history of mechanical mitral valve replacement who developed HMB. These patients were on stable warfarin regimens before the initiation of norethindrone and subsequently experienced increases in their international normalized ratio (INR). In response, they required an up to 50% reduction in their weekly warfarin dose over 5 to 12 weeks. CONCLUSION: These observations suggest that use of norethindrone for the management of HMB may significantly potentiate the anticoagulant effect of warfarin. Close INR monitoring and aggressive dose adjustments during initiation and discontinuation of norethindrone are recommended in patients on warfarin.
引用
- Grapsy J, Hoang A, Lee Y, et al. Potential drug-drug interaction between warfarin and norethindrone in adolescent females: A case series. Am J Health Syst Pharm. 2023. PMID: 36264703. doi:10.1093/ajhp/zxac303
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。